Voice your opinion on congressional bill HR1873-117 and let lawmakers know your stance with UnPac!

Main Subject: Health

Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

HR19-117, S164-117,

House committee actions Actions

Committee
Mar. 16 2021	Referred to the Subcommittee on Health.

House floor actions Actions

IntroReferral
Mar. 12 2021	Referred to the House Committee on Energy and Commerce.

Library of Congress Actions

IntroReferral
Mar. 12 2021	Introduced in House Introduced in House

House bill HR1873-117

Advancing Education on Biosimilars Act of 2021

Promote the cause!

Or use this QR code